Ferruccio Bonino
#155,995
Most Influential Person Now
Researcher
Ferruccio Bonino's AcademicInfluence.com Rankings
Ferruccio Boninocomputer-science Degrees
Computer Science
#8587
World Rank
#9028
Historical Rank
Machine Learning
#3556
World Rank
#3600
Historical Rank
Artificial Intelligence
#3864
World Rank
#3920
Historical Rank
Database
#5583
World Rank
#5793
Historical Rank
Download Badge
Computer Science
Ferruccio Bonino's Degrees
- PhD Computer Science University of Milan
- Masters Artificial Intelligence University of Turin
Similar Degrees You Can Earn
Why Is Ferruccio Bonino Influential?
(Suggest an Edit or Addition)Ferruccio Bonino's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. (2004) (1118)
- A proposed system for the nomenclature of hepatitis C viral genotypes (1994) (1100)
- Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. (1977) (836)
- Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases (2007) (670)
- Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. (1991) (651)
- Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein (2002) (493)
- Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B (2009) (430)
- Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. (2010) (385)
- Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. (2002) (360)
- Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. (1983) (357)
- Prevention of hepatocellular carcinoma recurrence with alpha‐interferon after liver resection in HCV cirrhosis (2006) (347)
- Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. (1986) (347)
- T-lymphocyte response to hepatitis C virus in different clinical courses of infection. (1993) (335)
- Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. (2009) (317)
- Hepatitis B virus DNA in the sera of HBsAg carriers: A marker of active hepatitis B virus replication in the liver (1981) (287)
- Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B (2006) (280)
- Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope (1986) (268)
- Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C (1993) (260)
- AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. (2017) (243)
- Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen (1989) (239)
- A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. (1990) (229)
- Long‐term follow‐up of patients with chronic hepatitis C treated with different doses of interferon‐α2b (1993) (163)
- Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. (2015) (156)
- Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography. (2010) (155)
- Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound. (1991) (152)
- Detection of intrahepatic replication of hepatitis C virus RNA by in situ hybridization and comparison with histopathology. (1992) (151)
- Transmission of the hepatitis B virus-associated delta agent to the eastern woodchuck. (1984) (150)
- Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. (1993) (145)
- Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. (2001) (135)
- Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. (2008) (134)
- Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients (2012) (133)
- Pathophysiology of Non Alcoholic Fatty Liver Disease (2016) (125)
- Human immunodeficiency virus infection as risk factor for mother‐to‐child hepatitis C virus transmission; Persistence of anti–hepatitis C virus in children is associated with the mother's anti–hepatitis C virus immunoblotting pattern (1995) (120)
- Delta hepatitis agent: structural and antigenic properties of the delta-associated particle (1984) (120)
- Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. (2005) (114)
- Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles (1997) (108)
- Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease (1996) (107)
- Type D hepatitis: The clinical significance of hepatitis D virus RNA in serum as detected by a hybridization‐based assay (1986) (102)
- Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination. (1997) (101)
- A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy (1989) (93)
- Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D (1991) (90)
- Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. (2013) (89)
- Chronic Hepatitis in Carriers of Hepatitis B Surface Antigen, with Intrahepatic Expression of the Delta Antigen (1983) (87)
- Relevance of inapparent coinfection by hepatitis B virus in alpha interferon‐treated patients with hepatitis C virus chronic hepatitis (1997) (83)
- Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. (1993) (79)
- Hepatitis B virus unable to secrete e antigen. (1991) (78)
- Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. (1987) (76)
- Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity. (1983) (76)
- Ribavirin treatment for chronic hepatitis D: a pilot study. (2008) (75)
- Recombinant interferon‐α2a hastens the rate of HBeAg clearance in children with chronic hepatitis B (1994) (73)
- Sequence variation in hepatitis C viral isolates. (1991) (73)
- A histological study of hepatitis delta virus liver disease (1986) (71)
- High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders (1996) (71)
- The δ agent: HBsAg particles with δ antigen and RNA in the serum of an HBV carrier (1981) (69)
- A "systems medicine" approach to the study of non-alcoholic fatty liver disease. (2016) (68)
- INHIBITION OF HEPATITIS B VIRUS REPLICATION BY VIDARABINE MONOPHOSPHATE CONJUGATED WITH LACTOSAMINATED SERUM ALBUMIN (1988) (67)
- Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: an Italian position statement. (2014) (64)
- Chronic HDV (hepatitis delta virus) hepatitis. Intrahepatic expression of delta antigen, histologic activity and outcome of liver disease. (1988) (64)
- Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. (2010) (63)
- The epidemiology of hepatitis delta infection in Italy over the last 18 years. (1992) (62)
- Circulating Hepatitis B Surface Antigen Particles Carry Hepatocellular microRNAs (2012) (62)
- Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. (2003) (62)
- Hemorheologic and Coagulative Pattern in Hypercholesterolemic Subjects Treated with Lipid-Lowering Drugs (1991) (58)
- Long term response to therapy of chronic anti-HBe–positive Hepatitis B is poor independent of type and schedule of interferon (1999) (56)
- HEPATITIS C VIRUS: A POSSIBLE CAUSE OF CHRONIC HEPATITIS IN ALCOHOLICS (1989) (56)
- A Multiphase Model of the Dynamics of HBV Infection in Hbeag-Negative Patients during Pegylated Interferon-α2A, Lamivudine and Combination Therapy (2005) (56)
- Hepatitis B virus DNA (HBV-DNA) in anti-HBe positive sera. (2008) (56)
- Replicating and virion secreting hepatitis B mutant virus unable to produce preS2 protein. (1991) (55)
- A precore‐defective mutant of hepatitis B virus associated with e antigen‐negative chronic liver disease (1990) (54)
- Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. (1995) (54)
- The natural history of chronic delta hepatitis. (1987) (54)
- Detection of HBV‐DNA by in situ hybridization using a biotin‐labeled probe (1985) (54)
- Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study (1998) (52)
- Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease (2015) (50)
- Treatment of chronic delta hepatitis with alpha-2 recombinant interferon. (1986) (50)
- Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection (1997) (49)
- Colon cancer seeding after percutaneous fine needle aspiration of liver metastasis. (1993) (47)
- Generation of an MHC class II-restricted T cell epitope by extracellular processing of hepatitis delta antigen. (1998) (46)
- Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects (1996) (46)
- Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs (1991) (46)
- Familiar clustering and spreading of hepatitis delta virus infection. (1985) (46)
- Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. (1998) (45)
- Long‐term outcome of inactive and active, low viraemic HBeAg‐negative‐hepatitis B virus infection: Benign course towards HBsAg clearance (2017) (43)
- Cytoplasmic Tubular Structures in Liver of HBsAg Carrier Chimpanzees Infected with Delta Agent and Comparison with Cytoplasmic Structures in Non‐A, Non‐B Hepatitis (2007) (43)
- Role of hepatitis delta virus infection in hepatocellular carcinoma (1991) (43)
- Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. (2012) (43)
- Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. (2003) (43)
- A Serum MicroRNA Signature Is Associated with the Immune Control of Chronic Hepatitis B Virus Infection (2014) (42)
- Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values. (1996) (41)
- Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor (1997) (41)
- Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay (2011) (41)
- Is high AgNOR quantity in hepatocytes associated with increased risk of hepatocellular carcinoma in chronic liver disease? (1993) (41)
- 103 VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A (40KD) WITH OR WITHOUT LAMIVUDINE: RESULTS OF 4-YEAR FOLLOW-UP (2008) (40)
- Sustained Response to Interferon–Ribavirin Combination Therapy Predicted by a Model of Hepatitis C Virus Dynamics Using Both Hcv Rna and Alanine Aminotransferase (2002) (39)
- A new hepatitis C virus‐like flavivirus in patients with cryptogenic liver disease associated with elevated GGT and alkaline phosphatase serum levels (1997) (39)
- Effects of a bicarbonate-alkaline mineral water on gastric functions and functional dyspepsia: a preclinical and clinical study. (2002) (38)
- Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial. (1998) (37)
- Identification of New Autoantigens by Protein Array Indicates a Role for IL4 Neutralization in Autoimmune Hepatitis* (2012) (37)
- Serial passage of hepatitis delta virus in chronic hepatitis B virus carrier chimpanzees (1988) (36)
- Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. (2007) (35)
- Liver Stiffness, a Non-Invasive Marker of Liver Disease: A Core Study Group Report (2010) (35)
- Diagnostic Markers of Chronic Hepatitis B Infection and Disease (2010) (34)
- Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C (2007) (34)
- The importance of hepatitis B viral DNA in serum and liver. (1986) (34)
- T cell receptor-therapy in HBV-related hepatocellularcarcinoma (2015) (34)
- 924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP (2009) (32)
- Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. (1999) (32)
- Levamisole and chronic delta hepatitis. (1983) (31)
- Experimental transmission of the delta agent to chimpanzees. (1983) (30)
- Hepatitis delta virus infection. (1990) (29)
- Intrahepatic markers of hepatitis delta virus infection: a study by in situ hybridization. (1989) (28)
- Hepatitis delta virus infection of the liver: progress in virology, pathobiology, and diagnosis. (1988) (28)
- Delta agent (type D) hepatitis. (1986) (28)
- Immunoperoxidase staining of the HBV-associated delta antigen in paraffinated liver specimens. (1981) (28)
- Serum markers of hepatitis B virus replication, liver histology and intrahepatic expression of hepatitis B core antigen. (1988) (27)
- Immunofluorescence detection of new antigen-antibody system (S/anti-5) associated to hepatitis B virus in liver and in serum of HBsAg carriers (2006) (27)
- Riboprobe assay for HDV RNA: A sensitive method for the detection of the HDV genome in clinical serum samples (1990) (26)
- Hepatitis C Virus Heteroduplex Tracking Assay for Genotype Determination Reveals Diverging Genotype 2 Isolates in Italian Hemodialysis Patients (1998) (25)
- Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies. (2003) (25)
- Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. (2007) (24)
- Intrahepatic markers of hepatitis delta virus infection: A study by in Situ hybridization (1989) (24)
- New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases. (2016) (24)
- The case for simplifying and using absolute targets for viral hepatitis elimination goals (2020) (24)
- [53] VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBeAg-NEGATIVE CHB TREATED WITH PEGINTERFERON a-2a (40 kD) ± LAMIVUDINE: 3-YEAR FOLLOW-UP RESULTS (2007) (23)
- Hepatotoxicity of intravenous cyclosporin A in patients with acute ulcerative colitis on total parenteral nutrition. (2008) (23)
- Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence. The European Cooperative Study Group on Liver Cancer and Transplantation. (2008) (22)
- Treatment with interferon of chronic hepatitis B associated with antibody to hepatitis B e antigen. (1991) (22)
- Albumin gene expression in liver tumors: diagnostic interest in fine needle aspiration biopsies. (1994) (22)
- Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations. (1993) (22)
- The delta agent: HBsAg particles with delta antigen and RNA in the serum of an HBV carrier. (1981) (21)
- Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridisation. (2008) (21)
- Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B. (1993) (21)
- Serological markers of HBV infectivity. (1987) (21)
- Gene Expression Profiling Reveals Multiple Protective Influences of the Peptide α-Melanocyte-Stimulating Hormone in Experimental Heart Transplantation1 (2005) (21)
- Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers. (2017) (21)
- Inhibition of hepatitis B virus replication by adenine arabinoside monophosphate coupled to lactosaminated albumin. Efficacy and minimal active dose. (1994) (20)
- HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial (2013) (20)
- Alteration in the Transcriptional Profile of Livers from Brain-dead Organ Donors (2006) (20)
- Quantitative analysis of wild‐type and HBeAg minus hepatitis B viruses by a sequence‐dependent primer extension assay (1994) (20)
- Complement fixing hepatitis B core antigen immune complexes in the liver of patients with HBs antigen positive chronic disease. (1976) (19)
- Hepatitis C virus infection and disease. Diagnostic problems. (1993) (19)
- Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. (2009) (19)
- Impact of interferon‐alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey (1997) (19)
- High prevalence of G1 and G2 TT-virus infection in subjects with high and low blood exposure risk: identification of G4 isolates in Italy. (1999) (18)
- Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging. (2018) (18)
- Complexes of hepatitis B surface antigen and immunoglobulin M in the sera of patients with hepatitis B virus infection (1983) (18)
- The epidemiology of hepatitis delta infection in Italy. Promoting Group. (1992) (18)
- Properties of delta-associated ribonucleic acid. (1983) (17)
- Detection of hepatitis delta virus RNA by a nonradioactive in situ hybridization procedure. (1992) (17)
- Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research (2018) (17)
- Propafenone-induced liver injury: report of a case and review of the literature. (1993) (17)
- Treatment of patients with chronic hepatitis C and cirrhosis. (1999) (17)
- Reduced Expression of the Melanocortin-1 Receptor in Human Liver during Brain Death (2006) (17)
- Precore Mutant Hepatitis B Virus and Outcome of Chronic Infection and Hepatitis in Hepatitis B e Antigen-Positive Children (1994) (17)
- Superimposed hepatitis and the effect on viral replication in chronic hepatitis B. (1986) (17)
- Clinical relevance of anti-interferon antibodies in the serum of chronic hepatitis C patients treated with interferon-alpha. (1997) (16)
- Relationship between the intrahepatic expression of 'e' and 'c' epitopes of the nucleocapsid protein of hepatitis B virus and viraemia. (1989) (16)
- Early and Accurate Prediction of Peg‐IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells (2008) (15)
- Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis. Investigators of the Alpha Interferon Study Group of Piemonte, Italy. (1997) (15)
- Localization of hepatitis C virus (HCV) antigen by immunohistochemistry on fixed-embedded liver tissue. (1990) (15)
- 95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine (2004) (14)
- Hepatitis delta virus pathogenicity. (1993) (14)
- Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences. (2004) (14)
- Pathobiology of chronic hepatitis virus infection and hepatocellular carcinoma (HCC). (1991) (14)
- Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection (2018) (14)
- Individualized Treatment of Hbeag-Negative Chronic Hepatitis B Using Pegylated Interferon-α2A as First-Line and Week-12 HBV Dna/Hbsag Stopping Rule: A Cost-Effectiveness Analysis (2013) (14)
- Proteins of hepatitis delta virus. (1987) (14)
- Serological diagnosis of hepatitis B and delta virus (HBV/HDV) coinfection. (1991) (14)
- A polymerase-chain reaction-based assay for serum HDV RNA. (1991) (14)
- Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis. (1994) (14)
- Expression of estrogen receptor mRNA in tumorous and non‐tumorous liver tissue as detected by in situ hybridization (1993) (14)
- Measles IgM immunoreactivity in patients with inflammatory bowel disease. (1998) (13)
- Hepatitis delta virus, a model of liver cell pathology. (1991) (13)
- Hepatitis delta virus heterogeneity: a study by immunofluorescence. (1991) (13)
- Genome-Wide Comparison of Next-Generation Sequencing and qPCR Platforms for microRNA Profiling in Serum. (2017) (13)
- Antibodies to hepatitis C virus in kidney transplantation. (1992) (12)
- The spectrum of complement‐fixing antinuclear antibodies in patients with hepatocellular carcinoma (1985) (12)
- Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. (2020) (11)
- A solid-phase enzyme immunoassay (EIA) for detection of HBeAg and anti-HBe. (1980) (11)
- Molecular markers of whv and hdv in single cells (1987) (11)
- Interferon Therapy of Chronic Hepatitis B (2014) (11)
- Coupling to lactosaminated poly-L-lysine reduces the toxic effects of ribavirin on red blood cells. (1998) (11)
- Increasing serum levels of IgM anti‐HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares (2003) (11)
- ALPHA INTERFERON IN THE TREATMENT OF CHRONIC DELTA HEPATITIS (1989) (10)
- 526 Liver stiffness measured by transient elastography. The influence of biochemical activity (2006) (10)
- Hepatitis C virus infection and liver disease: peculiar epidemiological and clinicopathological features. (1994) (10)
- Complexes between hbsag and igm in serum of patients with acute hepatitis (1983) (10)
- Italian Association for the Study of the Liver; Italian Society of Infectious,Tropical Diseases; Italian Society for the Study of Sexually TransmittedDiseases. Practice guidelines for the treatment of hepatitis C: recommendationsfrom an AISF/SIMIT/SIMAST Expert Opinion Meeting (2010) (9)
- Liver stiffness measured by transient elastography: The influence of biochemical activity (2006) (9)
- Hepatocellular carcinoma and infections with multiple hepatitis viruses. (1995) (9)
- CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a (2009) (9)
- IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus‐related disease? (1997) (8)
- Intramuscular natural beta interferon in the treatment of chronic hepatitis B: a multicentre trial. Italian Hepatitis B Study Group. (1994) (8)
- HBV pre‐core mutant in genotype‐D infected children is selected during HBeAg/anti‐HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood (2018) (8)
- Molecular analysis of VHI+ B lymphocytes in hepatitis C patients (2003) (8)
- Active HBV replication in HBsAg carriers with chronic Delta infection (1985) (8)
- Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon. (1997) (8)
- Towards a vaccine for the prevention of hepatitis delta virus superinfection in HBV carriers. (1993) (8)
- Natural killer response to exogenous interferon in delta hepatitis: boost or depression defined within the first week of therapy. (1987) (8)
- Prevalence of breakthrough in chronic hepatitis C patients undergoing antiviral therapy: role of type and schedule of alpha interferon C.H.S.G. (1997) (8)
- Leptin resistance before and after obesity: evidence that tissue glucose uptake underlies adipocyte enlargement and liver steatosis/steatohepatitis in Zucker rats from early-life stages (2021) (7)
- The prevalence of hepatitis C virus types in patients of the same geographic area, according to the source of infection and liver disease. (1997) (7)
- Immunohistochemical research on HDV infection in Chinese patients with chronic liver disease (1990) (7)
- Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D (1995) (7)
- Thermal Care of Functional Dyspepsia Based on Bicarbonate-Sulphate-Calcium Water: A Sequential Clinical Trial (2006) (7)
- Animal model for liver cell banking from non-heart beating donors after prolonged ischaemia time. (2006) (7)
- Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study. (1997) (7)
- The clinical and immunological significance of a new antigen/antibody system (delta/anti-delta) in chronic carriers of the HBsAg (1978) (7)
- Clinical evaluation of serum cationic trypsin-like immunoreactivity in patients with different pancreatic diseases (1980) (7)
- Is hepatitis C virus RNA detectable in dialysis ultrafiltrate? (1996) (7)
- Hepatitis delta virus (HDV) infection and hepatocellular carcinoma (HCC). (1991) (7)
- Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease (2021) (6)
- Is HCV-RNA detectable in dialysis ultrafiltrate? (1993) (6)
- Famciclovir treatment of anti-HBE+ chronic hepatitis B: Results of a randomized, placebo-controlled study (2000) (6)
- 1023 FACTORS RELATED TO LIVER STIFFNESS MEASUREMENT BY TRANSIENT ELASTOGRAPHY AMONG HEALTHY INDIVIDUALS: RESULTS FROM A PROSPECTIVE STUDY (2009) (6)
- Do the circulating Pre‐S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection? (2020) (6)
- PROGNOSTIC SIGNIFICANCE OF IN-VITRO COMPLEMENT FIXATION IN LIVER BIOPSY SPECIMENS FROM PATIENTS WITH ACUTE VIRAL HEPATITIS TYPE B (1976) (6)
- 1181 A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40KD) (PEGSYS®) alone or in combination with lamivudine vs lamivudine in 546 patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B (2003) (6)
- 683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY (2008) (6)
- Detection of cytomegalovirus by in situ hybridization using a digoxigenin-tailed oligonucleotide. (2008) (6)
- Preoperative serum levels of wild‐type and hepatitis B e antigen‐negative hepatitis B virus (HBV) and graft infection after liver transplantation for HBV‐related hepatocellular carcinoma (1997) (6)
- In situ hybridization in viral hepatitis. (1992) (6)
- Patterns of natural killer cell function activation in response to interferon in chronic HBsAG positive hepatitis: relationship with the state of viral infection and with the early clinical response. (1987) (6)
- Hepatitis B virus replication and clinical outcome in carriers of HBsAg. Perspectives of treatment with DNA inhibitors. (2008) (5)
- Hepatitis C virus infection and liver disease. (1995) (5)
- Presence and significance of hepatitis B virus replication in chronic type D hepatitis. (1991) (5)
- 94 Prospective randomised trial on IFN-therapy for the secondary prevention of HCC recurrence after curative resection in HCV related cirrhosis. Preliminary report (2004) (5)
- Guidelines for the treatment of chronic viral hepatitis (1997) (5)
- Clinical and epidemiological significance of hepatitis delta virus (HDV) infection in chronic HBV carriers in Portugal. (1987) (5)
- Thee antigen and antibody in the serum of patients with HBsAg-positive liver disease and in asymptomatic carriers (1976) (5)
- Factors related to liver stiffness values among healthy individuals: Results from a prospective study (2009) (5)
- Personalized therapy in chronic viral hepatitis. (2008) (5)
- Chronic anti-HBe hepatitis and serum HBV-DNA. A separate clinical entity (1985) (5)
- Long-term response to interferon-alfa 2b re-treatment in chronic hepatitis C. (1994) (5)
- Hepatitis C virus infection in type II essential mixed cryoglobulinemias. (1993) (5)
- Biological standards for hepatitis B virus assays. (1992) (5)
- The immunological diagnosis of HBsAg liver disease by combined screening for thee system in the serum and the HB core and surface antigens in liver biopsy samples (1977) (5)
- Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line. (2013) (4)
- Liver targeting of adenine arabinoside monophosphate (ara-AMP) by coupling to lactosaminated human serum albumin. (1995) (4)
- Different aspects of HDV and HBV reinfections and liver disease in orthotopic liver transplant (OLT). (1993) (4)
- A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C. (2015) (4)
- Expression of the c‐myc protooncogene product in cells infected with the hepatitis delta virus (1994) (4)
- Incidence and significance of different types of connective tissue antibodies in adult and pediatric gastroenterological disorders. (1978) (4)
- Possible immunopathogenesis for fibrosing cholestatic hepatitis. (1994) (4)
- Hepatitis B Virus Precore Mutants (1994) (4)
- Problems in diagnosing viral hepatitis. (1993) (4)
- Hepatitis C virus: Specificity and clinical significance of anti-C-100-3 and partial characterization of an Italian isolate (1990) (4)
- Variations in the hypervariable region 1 of the envelope region E2 of hepatitis C virus RNA appear associated with virus persistence independently of liver disease. (1996) (4)
- Treatment of woodchuck hepatitis virus infection in vivo with 2', -3'-dideoxycytidine (ddC) and 2',-3'-dideoxycytidine monophosphate coupled to lactosaminated human serum albumin (L-HSA ddCMP). (2008) (4)
- Pathobiology of hepatitis delta virus infection at the cell level. (1993) (4)
- Demonstration of specific detection of anti-HCV IgM core antibodies. (1996) (4)
- Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study. (2000) (4)
- Molecular analysis of V(H)I+ B lymphocytes in hepatitis C patients. (2003) (4)
- A HBV variant is responsible for anti-HBe positive hepatitis B (1989) (3)
- A Deep Learning Approach for Hepatic Steatosis Estimation from Ultrasound Imaging (2021) (3)
- Hepatitis D virus(HDV)/hepatitis B virus(HBV) interactions: A molecular and virologic study (1989) (3)
- Hepatitis C virus heteroduplex tracking assay : application to genotype determination, quasispecies analysis, and molecular evolution studies. (1999) (3)
- Hepatitis B virus infection markers in chronic liver disease in Italy. The results of a multiregional investigation (1984) (3)
- Introduction to ‘Hepatitis B virus heterogeneity – a means to personalized care’ (2010) (3)
- Maturation of the Visceral (Gut-Adipose-Liver) Network in Response to the Weaning Reaction versus Adult Age and Impact of Maternal High-Fat Diet (2021) (3)
- Wild-type and “o” antigen minus hepatitis B viruses and course of chronic hepatitis B in children (1991) (3)
- Characterization of hepatitis delta antigen gene of a highly pathogenic strain of hepatitis delta virus. (1991) (3)
- Delta virus infection in Jerusalem. (1988) (3)
- Liver stiffness values measured by transient elastography are increased in patients with acutely decompensated heart failure (2009) (3)
- Normal lymphocyte interferon production in adult HBsAg‐positive chronic active liver disease (1979) (3)
- Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine (2022) (3)
- In situ hybridizaiton in Viral hepatitis (2008) (3)
- Antiviral activity of ganciclovir, 9-(1,3-dihydroxy-2-propoxymethyl) guanine against woodchuck hepatitis virus: quantitative measurement of woodchuck hepatitis virus DNA using storage phosphor technology. (1998) (3)
- Hepatitis Delta Virus in Acute and Chronic Liver Disease (1989) (3)
- Safety of anti-HCV-reactive immunoglobulin in heart transplant patients (1992) (3)
- Treatment of chronic type B hepatitis, positive for the antibody to hepatitis B "e" antigen with alpha-2A-interferon. (1988) (3)
- 421 A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2A (40KD) (PEGASYS®), lamivudine, or PEGASYS® plus lamivudine combin (2004) (3)
- Usefulness of IgM anti-HCV in differential diagnosis between recurrent hepatitis C and acute rejection in liver transplant patients. (2001) (3)
- Overt and latent HBV infection. (1983) (3)
- Early prediction of sustained virologic response by HCV Core Ag kinetics in chronic hepatitis C patients treated with Peginterferon plus Ribavirin (2014) (2)
- DETECTION OF HEPATITIS C VIRAL RNA BY THE POLYMERASE CHAIN REACTION (1991) (2)
- Impact of antiviral treatment on recurrence of hepatitis B virus infection and disease. (2003) (2)
- Does HBeAg minus HBV modify the course of HDV superinfection? (1991) (2)
- Hepatocellular carcinoma and hepatitis delta virus infection (1989) (2)
- Hepatitis C virus infection in patients with haematological diseases: evidence for the association with erythrocytes transfusion and liver disease (1995) (2)
- [Evaluation of the usefulness of ultrasonics in the diagnosis of cancerous cirrhosis. Comparison with CT]. (1988) (2)
- Antibody to hepatitis C virus in the serum of patients with chponic hepatitis (1989) (2)
- A counterimmunoelectrophoretic technique for the detection of HBeAg/anti-HBeAg (e antigen/antibody) in human sera. (1977) (2)
- Reply to: "To target or not to target viral antigens in HBV related HCC?". (2015) (2)
- Chronic Delta Hepatitis (1983) (2)
- Modifications of the coagulative and rheologic pattern in hypercholesterolemic patients treated with bezafibrate R or simvastatin (1991) (2)
- Living-donor liver transplantation: to be or not to be. (2000) (2)
- Radioimmunoassay for the detection of HBeAg and anti-HBe. (1979) (2)
- Wild-type and HBeAg-minus HBV Fluctuations: Cause or Effect of Chronic Hepatitis B Pathogenic Mechanisms? (1994) (2)
- The Meanings of Mutations in and Around Pre-C/C and Pre-S/S Regions of HBV: Summary of a Specialty Session (1994) (2)
- One year experiencee in the treatmeent of elderly hypercholesterolemic patients with pravastatin (1991) (2)
- Validation and comparison of different PCR-based methods for detection of hepatitis B virus precore region mutants. (2005) (2)
- Factors influencing the natural course of HDV hepatitis. (1991) (2)
- Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib (2021) (2)
- Italian trials of interferon alpha in chronic delta hepatitis. (1993) (2)
- Monitoring antiviral non A non B chronic hepatitis therapy by HCV serum markers (1991) (2)
- Software and expert system for the management of chronic hepatitis B. (2005) (2)
- HBV heterogeneity and response to interferon (1991) (2)
- 602 THE CANDIDATE HCV E1E2MF59 VACCINE IS SAFE IN CHRONIC HEPATITIS C PATIENTS AND ACCELLERATES THE SECOND PHASE VIRAL DECLINE UPON PRIMARY RESPONSE TO PEG-INTERFERON-2A/RIBAVIRIN THERAPY (2009) (2)
- [Simultaneous inoculation of hepatitis B virus and non-A non-B agents on a chimpanzee: histopathology in relation to electron microscopic and immunologic findings]. (1981) (1)
- Antibodies against the human pancreas in acute and chronic liver disease (1975) (1)
- OC-25 Bio-mathematical modelling provides the most accurate selection of HCV-G1 patients for triple-therapy (2013) (1)
- [Is HCV RNA detectable in the ultrafiltrate?]. (1996) (1)
- Rabbit-derived anti-HD antibodies for HDAg immunoblotting. (1991) (1)
- Production and use of autologous gene modified T cells targeting metastatic hepatitis B associated hepatocellular carcinoma (2013) (1)
- Immunohistochemical research of HDV infection in Chinese patients with chronic liver disease. (1990) (1)
- 3 IMPROVED IN VITRO HBV REPLICATION IN HuH7 CELL LINE TRANSFECTED WITH FULL LENGTH CIRCULAR CLOSED HBV DNA BY MODIFICATIONS OF THE GUNTHER'S METHOD (2010) (1)
- [487] PREDICTORS OF HBsAg REDUCTION IN HBsAg- NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) ALONE OR IN COMBINATION WITH LAMIVUDINE (2007) (1)
- HCV infection in LKMI autoimmune hepatitis (AH) is confirmed by recombinant immunoblotting assay (RIBA) (1990) (1)
- Steatosis/steatohepatitis: how sustainable is the non-invasive instrumental differential diagnosis in clinical practice? (2021) (1)
- On the operational definition of fatty liver (2018) (1)
- Localization of hepatitis C virus antigen(s) by immunohistochemistry on fixed-embedded liver tissue. (1992) (1)
- 251 THERAPY WITH T CELL RECEPTOR GENE MODIFIED T CELLS TARGETING HBsAg-PRODUCING HCC METASTASES (2013) (1)
- Evidence of a Gastro-Duodenal Effect on Adipose Tissue and Brain Metabolism, Potentially Mediated by Gut–Liver Inflammation: A Study with Positron Emission Tomography and Oral 18FDG in Mice (2022) (1)
- Hepatitis delta virus (HDV) RNA species in liver and serum of patients with chronic type D hepatitis (1989) (1)
- IgM-specific antibody against measles virus in patients with inflammatory bowel disease (1995) (1)
- P.03.1 IN-HOUSE ALLELE SPECIFIC PCR METHOD TO STUDY THE KINETICS OF RESISTANT VARIANTS DURING NUCLEOS(T)IDE ANALOGS TREATMENT IN IMMUNOCOMPETENT AND IMMUNOCOMPROMISED PATIENTS (2012) (1)
- HBsAg/IgM complexes in serum of HBsAg carriers: partial characterization and clinical significance. (1983) (1)
- P.04.6 MODELING THE TIME-RELATED FLUCTUATIONS OF AFP AND PIVKA-II SERUM LEVELS IN PATIENTS WITH CIRRHOSIS UNDERGOING SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA (2019) (1)
- F.N.37 ACCURATE INDIVIDUALIZATION OF PEG-IFN+RBV TREATMENT DURATION BY HCV INFECTED CELL DECLINE COMPUTED IN THE 1ST MONTH OF THERAPY (2010) (1)
- Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease? [corrected]. (1996) (1)
- Interferon treatment of chronic hepatitis B surface antigen (HBsAg) carriers. A description of the activation profiles of natural killer cells obtained with different schedules of administration in three subsets of carriers (1987) (1)
- The hepatitis C virus carrier with "persistently" normal serum transaminases: a misleading clinical issue. (2000) (1)
- HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History (2022) (1)
- Use of interferon in chronic viral hepatitis. (1992) (1)
- Treatment of chronic hepatitis B with beta interferon given intramuscularly: a pilot study. (1992) (1)
- In hepatitis C infected patients with cirrhosis squamous cell carcinoma antigen (SCCA)-IgM levels may contribute to identify the individual risk of hepatocellular carcinoma development after antiviral therapy (2017) (1)
- Etiology of chronic liver disease and HCC biomarkers (2016) (1)
- Treating chronic liver disease: lessons from a day hospital. (1992) (1)
- [Influence of coffee on plasma lipids]. (1989) (1)
- Diagnostic advances in viral hepatitis: the discovery of hepatitis C virus and genetic heterogeneity of hepatitis B virus. (1991) (1)
- T-06 Early HCV-Core-Ag kinetics predict sustained virologic response in chronic hepatitis C patients treated with standard of care (2013) (1)
- Clinical significance of time related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma (2018) (1)
- The impact of molecular biology in the diagnosis and management of viral hepatitis (1988) (1)
- Highly dynamic changes of regional HBV epidemiology over two decades. (2022) (1)
- O.091 Early prediction of response to Peg-IFNα-2a or Peg-IFNα-2b plus ribavirin in the single chronic hepatitis C patients by modeling the dynamics of infected cells (2006) (1)
- P.04.23 VERY LOWPREVALENCE OF ACTIVE HCV INFECTION AMONG HEALTHCARE WORKERS IN A REGIONAL REFERENCE HOSPITAL OF TUSCANY, ITALY (2019) (1)
- Severe liver injury possibly due to verapamil (1986) (1)
- 215 LIVER STIFFNESS VALUES MEASURED BY TRANSIENT ELASTOGRAPHY ARE INCREASED IN PATIENTS WITH ACUTELY DECOMPENSATED HEART FAILURE (2009) (1)
- Distribution of antibodies against the delta-antigen in HBsAg carriers detected by a simple immunofluorescence blocking test. (1978) (1)
- Delta virus infection in Jerusalem. (1987) (1)
- Immunoblotting for the hepatitis delta antigen: diagnostic role. (1991) (1)
- P.09.25 MACHINE LEARNING APPROACHES FOR NON-INVASIVE ULTRASOUND-BASED QUANTITATIVE ASSESSMENT OF LIVER STEATOSIS (2018) (1)
- Chronic viral hepatitis. From clinical trials to the therapeutic decision in the individual patient. (1991) (1)
- A PCR analysis of reinfection and liver disease in liver transplant (OLT) due to hepatitis viruses (1991) (1)
- P.362 Liver stiffness measured by transient elastography: the influence of biochemical activity (2006) (0)
- Book Review:Hepadnaviruses: Molecular Biology and Pathogenesis. W. S. Mason, C. Seeger (1992) (0)
- Treatment of chronic hepatitis B: an update (2005) (0)
- P.017 Lamivudine monotherapy can favour the emergence of viral quasispecies with lower susceptibility to other nucleos(t)ide analogues (2006) (0)
- [Surface antigen (HBsAg) and core antigen (HBcAg) of the Dane particle detected by immunofluorescence in hepatic biopsies in patients with acute and chronic hepatitis]. (1976) (0)
- Dynamics of hepatitis C virus and alanine amino transferase during alpha interferon therapy. (2001) (0)
- Liver and White/Brown Fat Dystrophy Associates with Gut Microbiota and Metabolomic Alterations in 3xTg Alzheimer’s Disease Mouse Model (2022) (0)
- 392 HBeAg defective mutants in active/inactive anti-HBe positive HBV carriers: Possible role of pre-core initiation mutants (2006) (0)
- OC-19 Modelling HCV kinetics by IL28B genotype is a new accurate tool for individual treatment management (2011) (0)
- The control of HBV replication that leads to HBeAg loss does not prevent the emergence of pre-core defective variants in genotype d infected children (2008) (0)
- Early prediction of sustained response in chronic hepatitis C patients treated with pegilated IFNs (A-2B or A-2A) plus ribavirin using a bio-mathematical model that describes the dynamics of infected cells (2006) (0)
- 249 ACCURATE PERSONALIZATION OF PEG-IFN+RBV TREATMENT DURATION BASED ON THE DECLINE OF HCV INFECTED CELLS COMPUTED DURING THE 1ST MONTH OF THERAPY (2010) (0)
- Anticomplementary Activity and Complementemia in Patients with Chronic Liver Disease (1976) (0)
- Early HCV-RNA kinetics after liver transplantation correlate with the outcome of recurrent hepatitis C (2003) (0)
- Quantitative PCR for hepatitis virus nucleic acids: state of the art (1997) (0)
- Farewell to the Italian journal of gastroenterology and hepatology. Welcome to digestive and liver disease (2000) (0)
- 639 MODELLING INFECTED CELL DYNAMICS BY WEEK 4 HCV RNA AND ALT KINETICS ALLOWS FOR INDIVIDUAL TAILORING OF TREATMENT DURATION IN CHRONIC HEPATITIS C PATIENTS (2009) (0)
- Transmission of the hepatitis B virus-associated 6 agent to the eastern woodchuck ( chronic viral hepatitis / animal model / hepadnavirus ) (0)
- FRI-122-Sarcopenia improves after sustained virologic response to DAAs in chronic hepatitis C patients with cirrhosis, but not in those who develop HCC (2019) (0)
- AF.84 BIOIMAGING, BIOCHEMICAL AND GENETIC MARKERS TO STRATIFY PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN CLINICAL PRACTICE: A SINGLE CENTER COHORT STUDY (2021) (0)
- AF.96 MODELING HEPATOCELLULAR CARCINOMA CELLS DYNAMICS BY SEROLOGICAL AND IMAGING BIOMARKERS TO EXPLAIN COMPLETE RESPONSE TO SORAFENIB (2021) (0)
- Modeling hepatocellular carcinoma cells dynamics by serolo-gical and imaging biomarkers in patients with response to sorafenib and/or regorafenib (2021) (0)
- 357 PRE-S HBV MUTANTS DO NOT AFFECT HBSAG SERUM LEVELS IN HBEAG NEGATIVE GENOTYPE D CARRIERS, BUT ARE ASSOCIATED WITH LIVER DISEASE STAGE AND OLDER AGE (2011) (0)
- P.1.98: EPIDEMIOLOGY AND SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA: A SINGLE CENTRE COHORT STUDY (2011) (0)
- P1202 EARLY PREDICTION OF SUSTAINED VIROLOGIC RESPONSE BY HCV CORE ANTIGEN KINETICS IN CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGINTERFERON PLUS RIBAVIRIN (2014) (0)
- Human Specific CD4+ T Cell Response to Hepatitis Delta Virus (1996) (0)
- Aspetti endoscopici dell'ulcera bulbare (1973) (0)
- Efficacy and tolerability of lactosaminated-human serum albumin-ara-MP (L-HSA-ara-MP) in the treatment of chronic hepatitis B (CHB) (2000) (0)
- HBsAg kinetics during and after nucleos(t)ide analogues described by mathematical modeling (2023) (0)
- Identification and consumption of hepatopathic patients in Tuscany Region: Limits and opportunities of administrative data (2013) (0)
- Low viremic HBeAg negative HBsAg carriers: Clinical outcome and non invasive diagnostic accuracy for chronic hepatitis B or inactive infection by combinations of HBV markers (2017) (0)
- Hcv Genotypes in Italian Patients With Chronic Hcv Infection: A Prospective Multicentre Study (1996) (0)
- Rabbit-derived anti- antibodies for (1991) (0)
- A new mathematical description of virus-host interaction in HCV infection that fits experimental data (2001) (0)
- HBV replication influences the course of chronic hepatitis D (1991) (0)
- Changing demographic-clinic-pathologic profiles of newly diagnosed carriers of chronic hepatitis B virus infection across two decades: a single regional reference center report (2021) (0)
- The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin (2009) (0)
- Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy (1999) (0)
- The early decrease of hepatitis C virus core antigen in the serum of chronic hepatitis C patients predicts drug efficacy and primary response to antiviral therapy (2002) (0)
- T06.01.22 THREE HBSAG KINETIC PROFILES IN HBEAG NEGATIVE INFECTION AND CHRONIC HEPATITIS ARE ASSOCIATED WITH DIFFERENT CHANCES OF HBSAG CLEARANCE (2020) (0)
- Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer (2004) (0)
- OC.01.6 THE CT1 MULTI-PARAMETRIC MRI VALUE IS MORE SENSITIVE AND RELIABLE THAN TRANSIENT ELASTOGRAPHY FOR THE NON-INVASIVE MONITORING OF INTRA-HEPATIC INFLAMMATION/FIBROSIS RESPONSE TO DAA THERAPY IN CHC PATIENTS (2019) (0)
- Mathematical modeling of cancer cells and vasculature dynamics with serological and imaging biomarkers suggests synergistic effects of TACE and TKIs in HCC patients (2022) (0)
- Prognostic factors after resection of hepatocellular carcinoma (HCC) in cirrhosis (1989) (0)
- The International Interferon alfa Hepatocellular Carcinoma Study Group (1998) (0)
- P.112 Response is sustained two years post-treatment in the majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] (2006) (0)
- HBsAg clearance in HBeAg negative infection and treated chronic hepatitis B is associated with different HBsAg kinetics (2020) (0)
- New Diagnostic Techniques: Hepatitis B Virus-DNA in Serum and Liver (1986) (0)
- AF.89 CHANGING DEMOGRAPHIC-CLINIC-PATHOLOGIC PROFILES OF NEWLY DIAGNOSED CARRIERS OF CHRONIC HEPATITIS B VIRUS INFECTION ACROSS TWO DECADES: A SINGLE ITALIAN REFERENCE CENTER REPORT (2021) (0)
- Maternal High-Fat Feeding Affects the Liver and Thymus Metabolic Axis in the Offspring and Some Effects Are Attenuated by Maternal Diet Normalization in a Minipig Model (2021) (0)
- Accumulation of a cellular protein bearing c-myc-like antigenicity in hepatic and non-hepatic delta antigen expressing cells. (1993) (0)
- Rapidly progressive HBsAg hepatitis in Italy: a syndrome of Delta hepatitis virus superinfection (1986) (0)
- 1171 Molecular epidemiology of hepatitis B virus in patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B from different geographical areas. Data from the PEGASYs® study in HBE-antigen-negative CHB (2003) (0)
- Occult Hepatitis B Virus (HBV) Infections: Hepatitis B Surface Antigen (HBsAg) Negative and Primary Occult (2013) (0)
- Molecular diagnostics in hepatitis C virus infection: clinical applications. Scientific Committee--"Tecnologie molecolari nella diagnostica delle epatopatie" of the Italian Association for the Study of the Liver-AISF. (1997) (0)
- Nucleic acid hybridization in viral Hepatitis research (1988) (0)
- Budget Impact of an Individualized Approach in the Treatment of HBeAg-Negative CHB Patients Exploiting the Week-12 Peginterferon Alfa-2a Stopping Rule in Italy (2013) (0)
- Conclusion to ‘Hepatitis B virus heterogeneity – a means to personalized care’ (2010) (0)
- Chronic hepatitis B treatment individualization by means of serum HBsAg and MiR-B-Index kinetics (2015) (0)
- Recurrence of hepatitis B after liver transplantation is associated with intrahepatic HBcAg and serum IgM anti-HBc (2001) (0)
- Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis (2022) (0)
- [Use of virus-induced damage markers in the diagnosis of viral hepatitis]. (1995) (0)
- PIN70 Cost-Effectiveness of an Individualized Approach in the Treatment of HBeAg-Negative CHB Patients With Peginterferon Alfa-2A in Italy (2012) (0)
- Low Anisakis-specific IgE prevalence in dyspeptic patients in Italy – a retrospective study (2018) (0)
- Outcome of chronic anti-HBe positive hepatitis B (2000) (0)
- Non-inyasive doppler us evaluation of portal flow in posthepatitic (HC), alcoholic (AC) and primary biliary (PBC) cirrhosis (1989) (0)
- P.04.1 IL28B POLYMORPHISM IN CHRONIC HBV INFECTION: THE CC ALLELE DOES NOT CORRELATE WITH THE PHASE OF THE INFECTION NOR WITH HBSAG CLEARANCE IN IFN TREATED PATIENTS (2012) (0)
- Transient elastography improves the management of CHB patients (2007) (0)
- the 'Hepatitis B virus heterogeneity - a means to personalized care‚steering committee. Conclusion to 'Hepatitis B virus heterogeneity - a means topersonalized care' (2010) (0)
- A single center, large long-term cohort study of the relations between mutations in Basic-Core-Promoter and pre-C regions of Hepatitis B virus DNA and clinic-pathologic outcome of HBeAg-negative/anti-HBe-positive phase (2021) (0)
- Liver transplantation in genetic defects of hepatocytes. (2003) (0)
- Colorectal cancer. A novel approach to adjuvant chemotherapy with fluoropyrimidines. (2002) (0)
- Machine learning approaches for non-invasive ultrasound. Based quantitative assessment of liver steatosis (2018) (0)
- Rheologic, haemostatic, and coagulative variables in type II hyperlipoproteinemic subjects (1994) (0)
- The impact of hepatitis B virus (HBV) and hepatitis C virus (HCV) : from research to clinical practice. (2000) (0)
- Hepatocyte isolation from the livers of non-heart beating rats after prolonged cold ischemia (2005) (0)
- Hepatitis delta virus infection. (1987) (0)
- Different rate of infection recurrence and disease outcome of hepatitis B and C viruses after liver transplantation (1999) (0)
- Anti-hepatitis C virus in nonAnonB patients responding and non-responding to alpha-2A interferon (1989) (0)
- Budget impact analysis of a personalized HBeAg negative CHB antiviral therapy model (2013) (0)
- HBeAg defective mutants in active/inactive anti-HBe positive HBsAg carriers: possible role of pre-core initiation mutants (2006) (0)
- Benign course of HBV reactivations during DAAs in untreated ENI with HBV-HCV co-infections correlates with different HBsAg kinetics compared to NAs treated CHB patients (2022) (0)
- Viral hepatitis and delta infection. Proceedings of an International Symposium on Viral Hepatitis. June 10-11, 1983, Torino, Italy. (1983) (0)
- P.04.12 HBSAG SERUM LEVEL AND HBV GENE S QUASISPECIES IN THE HBEAG NEGATIVE PHASE OF CHRONIC GENOTYPE D HBV INFECTION (2019) (0)
- Long-term outcome of inactive and low viremic HBeAg negative active carriers: Benign one direction transition towards spontaneous HBsAg clearance (2014) (0)
- F11-11 Treatment of chronic hepatitis C (1995) (0)
- Cancer cells and tumor vasculature dynamics analyzed by bio-mathematical modeling in HCC patients with different response to TKIs, TACE and TARE (2022) (0)
- OC.04.9 A SINGLE CENTER, LARGE LONG TERM COHORT STUDY OF THE RELATIONS BETWEEN MUTATIONS IN BASIC-CORE-PROMOTER AND PRE-C REGIONS OF HEPATITIS B VIRUS DNA AND CLINICPATHOLOGIC OUTCOME OF HBEAG-NEGATIVE/ANTI-HBEPOSITIVE PHASE (2021) (0)
- Application Of Nucleic acid hybridization to the hepatitis δ virus research (1988) (0)
- Heart Transplantation-Melanocyte-Stimulating Hormone in α Protective Influences of the Peptide Gene Expression Profiling Reveals Multiple and (2005) (0)
- Identification and characterization of a HBV pre S2/pre-C double mutant in a chronic carrier (1991) (0)
- Diagnostic tools from molecular biology. (2008) (0)
- Dynamic fluctuations of IgM anti-HCV helps to distinguish hepatitis C from rejection in liver transplant patients (2000) (0)
- Dynamic analysis of HCV-RNA, TTV-DNA and transaminases serum levels in patients with chronic hepatitis: Evidence for occasional pathogenicity of TTV. (1999) (0)
- The relative prevaleece of wild hepatitis B virus and its nutant unable to secrete WBeAg condition the course and outcome of ceronic infection of hepatitis B and delta viruses (1990) (0)
- Liver stiffness, a non-invasive marker of liver disease in the HBV carrier (2008) (0)
- 28 Early HCV-RNA kinetics after liver transplantation correlates with the outcome of recurrent hepatitis C (2003) (0)
- P688 LONG-TERM OUTCOME OF INACTIVE AND LOW VIREMIC HBeAg NEGATIVE ACTIVE CARRIERS: BENIGN ONE DIRECTION TRANSITION TOWARDS SPONTANEOUS HBsAg CLEARANCE (2014) (0)
- Modelling infected cell dynamics by week 4 HCV RNA and ALT kinetics to compute treatment duration (2009) (0)
- AgNOR proliferation index and development of hepatocellular carcinoma in cirrhosis (1998) (0)
- Clinical significance of time related fluctuations of AFP and PIVKA-II serum levels in single patients with cirrhosis undergoing surveillance for hepatocellular carcinoma (2018) (0)
- [Chronic hepatitis: diagnostic and therapeutic problems]. (1975) (0)
- Interferon for HBeAg-negative chronic hepatitis B: Teaching an old trick to an old dog? (2005) (0)
- Application of nucleic acid hybridization to the hepatitis delta virus research. (1988) (0)
- Variants of hepatitis B virus. (1992) (0)
- Tesi di Specializzazione in Gastroenterologia Direttore: Prof. Santino Marchi TITOLO: IL28B polymorphism in chronic HBV infection: the CC allele does not correlate with the phase of the infection nor with HBsAg clearance in IFN treated patients (2012) (0)
- Prevention of recurrence of hepatitis B after liver transplantation using HBIg with or without lamivudine (2001) (0)
- Antigen Epitope by Extracellular Processing of Hepatitis Generation of an MHC Class II-Restricted T Cell (1998) (0)
- c-myc expression in cells infected with hepatitis delta virus. (1993) (0)
- Enzootic calcinosis of sheep in Uruguay. (2011) (0)
- T06.01.21 PNPLA3 COULD HELP THE CLINICIANS TO INDIVIDUATE NAFLD SUBJECTS AT MAJOR RISK OF DISEASE PROGRESSION: A SINGLE CENTER CHOHORT STUDY (2020) (0)
- Monitoring HCV-RNA levels during the first month of treatment identifies primary responders to interferon (1998) (0)
- Uridine diphosphate glucoronosyl transferases, candidate antigens of liver‐kidney microsomal antibodies in hepatitis delta virus‐infected patients (1995) (0)
- Cost-Effectiveness Analysis Of A Personalized Therapy For Genotype 1, Naive, Chronic Hepatitis C Patients In Italy. (2014) (0)
- Quantitative HBV/HDV markers help to distinguish different clinic/virologic phases of chronic hepatitis delta (2023) (0)
- Hepatitis delta virus : molecular biology, pathogenesis, and clinical aspects : proceedings of the Fourth International Symposium on Heptitis Delta Virus, held at Rhodes, Greece, June 8-10, 1992 (1993) (0)
- Efficacy of crenotherapy with uliveto water in functional dyspepsia (2000) (0)
- 682 HBVDNA SUPPRESSION INDUCED BY PEGINTERFERON ALFA-2A (40KD) BUT NOT BY LAMIVUDINE RESULTS IN HBSAG LOSS AND SEROCONVERSION AT 3 YEARS POST-TREATMENT (2008) (0)
- Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapy (2016) (0)
- [Anatoma-clinical correlations in patients with liver diseases with circulating antibodies studied in regional case records]. (1976) (0)
- T06.01.10 DATA DRIVEN MODEL OF NEOPLASTIC CELLS DYNAMICS BY CIRCULATING AND IMAGING BIOMARKERS OF HEPATOCELLULAR CARCINOMA: A PROMISING TOOL FOR INDIVIDUALIZED THERAPY (2020) (0)
- Genome-wide comparison of NGS and qPCR platforms for microRNA profiling in serum (2016) (0)
- MiR-B-index: A candidate bio-marker to identify the immune control of HBV infection in chronic hepatitis B patients treated with nucleos(t)ide-analogues (2016) (0)
- Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy (2022) (0)
- FATTY LIVER AND GUT MICROBIOTA: A NEW MULTI-DIMENSIONAL APPROACH FOR PERSONALIZED PREVENTIVE MEDICINE (2019) (0)
- In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy (2017) (0)
- Transient elastography as a new tool to monitor HBV carriers (2008) (0)
- Ultrasound-based assessment of hepatic steatosis : a deep learning approach (2019) (0)
- Non-invasive Quantification of Steatosis: A New Ultrasound based Model to Predict Fatty Liver Content (2022) (0)
- 127 TREATMENT OF CHRONIC TYPE B HEPATITIS WITH RECOMBINANT ALPHA 2a INTERFERON IN HBeAg POSITIVE CHILDREN (1990) (0)
- 646 THE CONTROL OF HBV REPLICATION THAT LEADS TO HBEAG LOSS DOES NOT PREVENT THE EMERGENCE OF PRE-CORE DEFECTIVE VARIANTS IN GENOTYPE D INFECTED CHILDREN (2008) (0)
- Nutritional intervention in the management of non-alcoholic fatty liver disease. (2023) (0)
- Non-invasive, non-ionizing fatty liver assessment by means of a new ultrasound-based imaging system: The Steatometer (2017) (0)
- P1-221 Association between dementia and cancer (2006) (0)
- [The relationships between the lipoprotein profile and rheological-coagulation parameters in patients with hyperlipoproteinemia type II]. (1992) (0)
- Decision-Making Algorithm and Predictive Model to Assess the Impact of Infectious Disease Epidemics on the Healthcare System: The COVID-19 Case Study in Italy (2022) (0)
- Monitoring liver steatosis by means of a new ultrasound imaging system (Steatometer) in HCV treated patients (2016) (0)
- Delta and non-A, non-B hepatitis viruses (1988) (0)
- Hepatitis C virus infection: early diagnosis and identification of response to antiviral therapy (2001) (0)
- The colostomized patient:a psycological and psycopathological investigation (1985) (0)
- IBD and colorectal W 54-W 63 W 54 MESALAZINE RELEASE FROM COATED TABLETS : EFFECT OF DRUGS WICH ALTER GASTROINTESTINAL (0)
- A dynamic analysis of IgM anti-HCV helps to distinguish hepatitis C from acute rejection in liver transplant patients (2001) (0)
- P.029 HBeAg defective mutants in active/inactive anti-HBe positive HBV carriers: possible role of pre-core initiation mutants (2006) (0)
- [Endoscopic aspects of the bulbar ulcer]. (1973) (0)
- SAT-432-The CT1 multi-parametric MRI value is more sensitive and reliable than transient elastography for the non-invasive monitoring of intra-hepatic inflammation/fibrosis response to DAA therapy in CHC patients (2019) (0)
- 632 AETIOLOGY OF CHRONIC LIVER DISEASE INFLUENCES CLINICAL PRESENTATION AND OUTCOME OF HEPATOCELLULAR CARCINOMA: A SINGLE CENTER COHORT STUDY (2013) (0)
- Economic evaluation of the chronic hepatitis B treatment strategies in Italy (2013) (0)
- Three HBsAg kinetic profiles in HBeAg negative infection and chronic hepatitis are associated with different chances of HBsAg clearance (2020) (0)
- Steatometer: A New Ultrasound Imaging System for Non Invasive, Non-Ionizing Fatty Liver Measurement (2016) (0)
- High efficacy of combination lamivudine and hepatitis B immunoglobulin in the prophylaxis of hepatitis B recurrence after liver transplantation. (2001) (0)
- OC.09.5: PRE-S HBV MUTANTS DO NOT AFFECT HBSAG SERUM LEVELS IN HBEAG NEGATIVE GENOTYPE D CARRIERS, BUT ARE ASSOCIATED WITH LIVER DISEASE STAGE AND OLDER AGE (2011) (0)
- [514] PREDICTION OF LIVER HISTOPATHOLOGY BY NON-INVASIVE MODELS IN HBeAg-POSITIVE AND HBeAg-NEGATIVE CHRONIC HEPATITIS B (2007) (0)
- OC.09.3: MODELLING HCV DYNAMICS ACCORDING TO IL28B POLYMORPHISM SHOWS DIFFERENT ANTIVIRAL EFFECTS OF PEGIFNS/RIBAVIRIN AND PROVIDES A NEW ACCURATE TOOL FOR TREATMENT MANAGEMENT (2011) (0)
- Hepatitis C virus :clinical significance of anti-HCV and HCV-RNA and characterization of an Italian isolate (1989) (0)
- Modeling the Dynamics of HCV Infected Cells to Tailor Antiviral Therapy in Clinical Practice: Can This Approach Fit for Neoplastic Cells? (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ferruccio Bonino?
Ferruccio Bonino is affiliated with the following schools:
